Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Fundamental Analysis

NASDAQ:PYXS - Nasdaq - US7473241013 - Common Stock - Currency: USD

1.17  +0.03 (+2.63%)

After market: 1.17 0 (0%)

Fundamental Rating

2

Taking everything into account, PYXS scores 2 out of 10 in our fundamental rating. PYXS was compared to 558 industry peers in the Biotechnology industry. While PYXS seems to be doing ok healthwise, there are quite some concerns on its profitability. PYXS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PYXS had negative earnings in the past year.
In the past year PYXS has reported a negative cash flow from operations.
In the past 5 years PYXS always reported negative net income.
In the past 5 years PYXS always reported negative operating cash flow.
PYXS Yearly Net Income VS EBIT VS OCF VS FCFPYXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -70.09%, PYXS is doing worse than 64.27% of the companies in the same industry.
Looking at the Return On Equity, with a value of -92.37%, PYXS is in line with its industry, outperforming 47.22% of the companies in the same industry.
Industry RankSector Rank
ROA -70.09%
ROE -92.37%
ROIC N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
PYXS Yearly ROA, ROE, ROICPYXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

PYXS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYXS Yearly Profit, Operating, Gross MarginsPYXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

PYXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PYXS has been increased compared to 1 year ago.
Compared to 5 years ago, PYXS has more shares outstanding
PYXS has a worse debt/assets ratio than last year.
PYXS Yearly Shares OutstandingPYXS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PYXS Yearly Total Debt VS Total AssetsPYXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

PYXS has an Altman-Z score of -3.86. This is a bad value and indicates that PYXS is not financially healthy and even has some risk of bankruptcy.
PYXS has a Altman-Z score of -3.86. This is comparable to the rest of the industry: PYXS outperforms 45.60% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that PYXS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, PYXS is in line with its industry, outperforming 47.40% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.86
ROIC/WACCN/A
WACC9.02%
PYXS Yearly LT Debt VS Equity VS FCFPYXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

PYXS has a Current Ratio of 7.75. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
PYXS's Current ratio of 7.75 is fine compared to the rest of the industry. PYXS outperforms 69.12% of its industry peers.
A Quick Ratio of 7.75 indicates that PYXS has no problem at all paying its short term obligations.
PYXS's Quick ratio of 7.75 is fine compared to the rest of the industry. PYXS outperforms 69.48% of its industry peers.
Industry RankSector Rank
Current Ratio 7.75
Quick Ratio 7.75
PYXS Yearly Current Assets VS Current LiabilitesPYXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

PYXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.82%, which is quite good.
Looking at the last year, PYXS shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)8.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-483.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to decrease by -0.82% on average over the next years.
Based on estimates for the next years, PYXS will show a very strong growth in Revenue. The Revenue will grow by 39.00% on average per year.
EPS Next Y-44.09%
EPS Next 2Y-10.73%
EPS Next 3Y-8.39%
EPS Next 5Y-0.82%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-18.78%
Revenue Next 5Y39%

3.3 Evolution

PYXS Yearly Revenue VS EstimatesPYXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PYXS Yearly EPS VS EstimatesPYXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PYXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PYXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYXS Price Earnings VS Forward Price EarningsPYXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYXS Per share dataPYXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

PYXS's earnings are expected to decrease with -8.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.73%
EPS Next 3Y-8.39%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PYXS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PYXIS ONCOLOGY INC

NASDAQ:PYXS (6/20/2025, 8:00:02 PM)

After market: 1.17 0 (0%)

1.17

+0.03 (+2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners38.31%
Inst Owner Change-2.5%
Ins Owners6.68%
Ins Owner Change0%
Market Cap72.48M
Analysts84.62
Price Target6.32 (440.17%)
Short Float %13.47%
Short Ratio13.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.71%
Min EPS beat(2)-16.32%
Max EPS beat(2)25.73%
EPS beat(4)2
Avg EPS beat(4)3.06%
Min EPS beat(4)-16.32%
Max EPS beat(4)25.73%
EPS beat(8)5
Avg EPS beat(8)18.67%
EPS beat(12)6
Avg EPS beat(12)14.89%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.89%
PT rev (3m)-28.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.37%
EPS NY rev (1m)-17.21%
EPS NY rev (3m)-2.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-1.24
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS1.66
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -70.09%
ROE -92.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.75
Quick Ratio 7.75
Altman-Z -3.86
F-Score1
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)419.47%
Cap/Depr(5y)331.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-483.33%
EPS Next Y-44.09%
EPS Next 2Y-10.73%
EPS Next 3Y-8.39%
EPS Next 5Y-0.82%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-18.78%
Revenue Next 5Y39%
EBIT growth 1Y-28.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-192.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.77%
OCF growth 3YN/A
OCF growth 5YN/A